Did Chelsea Handler confirm she used Ozempic?

Yes. Handler publicly confirmed in January 2023 that she had been prescribed Ozempic by an anti-aging physician. She stated she was not initially aware the injection was semaglutide and discontinued it after learning what it was.

Was Handler's Ozempic use on-label or off-label?

Off-label. Handler has no publicly disclosed type 2 diabetes diagnosis. Ozempic is FDA-approved for type 2 diabetes management. When prescribed for weight loss in patients without diabetes, it constitutes off-label use. Wegovy (semaglutide 2.4 mg) is the FDA-approved formulation for chronic weight management.

What happens when you stop taking Ozempic?

Clinical trial data from the STEP 1 extension study showed that participants regained approximately two-thirds of lost weight within one year of discontinuing semaglutide. Appetite suppression, the primary mechanism driving weight loss, reverses when the drug is stopped. The HealthRX Medical Team emphasizes that discontinuation planning should be part of the initial prescribing conversation.

Can any doctor prescribe Ozempic for weight loss?

Any licensed physician can legally prescribe Ozempic off-label. The clinical question is whether the prescriber has adequate training to screen for contraindications, manage side effects, monitor metabolic parameters, and plan for long-term treatment. The HealthRX Medical Team recommends patients confirm their prescriber conducts baseline metabolic labs and has a structured follow-up protocol.

Is Ozempic the same as Wegovy?

Both contain semaglutide manufactured by Novo Nordisk. Ozempic is approved for type 2 diabetes (doses up to 2 mg/week). Wegovy is approved for chronic weight management (2.4 mg/week). The molecule is identical, but the approved indications, dosing, and insurance coverage differ.

Chelsea Handler and GLP-1: The Documented Public Record

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Chelsea Handler Has Publicly Confirmed

In January 2023, Handler discussed her experience with Ozempic during an appearance on the Call Her Daddy podcast, stating that her "anti-aging doctor" had prescribed her an injection she did not initially realize was semaglutide. She described taking the medication for a period before a friend identified it as Ozempic. Handler said she then stopped using it.

Handler was candid about the circumstances. She told host Alex Cooper that she "didn't even know" she was on Ozempic, framing the experience as an example of how medications can be prescribed without patients fully understanding what they are receiving. In subsequent interviews through early and mid-2023, she repeated this account consistently, including during her appearance on The Tonight Show.

The confirmed facts from Handler's own public statements:

She was prescribed semaglutide (brand name Ozempic) by a physician she described as an "anti-aging doctor."
The prescription was off-label, as Handler has no publicly disclosed diagnosis of type 2 diabetes.
She was not initially aware the injection was Ozempic specifically.
She discontinued the medication after learning its identity.

There is no public record of Handler using tirzepatide (Mounjaro), liraglutide (Saxenda), or any other GLP-1 receptor agonist. Her confirmed use is limited to semaglutide in its Ozempic formulation.

The Clinical Reality of Off-Label GLP-1 Prescribing

Handler's story is not unusual from a prescribing-pattern standpoint. Before the FDA approved Wegovy (semaglutide 2.4 mg) specifically for chronic weight management in June 2021, physicians had already been writing off-label Ozempic prescriptions for patients without diabetes. Even after Wegovy's approval, supply shortages through 2022 and 2023 pushed many prescribers toward Ozempic as a substitute, a practice the FDA addressed in public communications.

Semaglutide is a glucagon-like peptide-1 receptor agonist that mimics the incretin hormone GLP-1. It slows gastric emptying, reduces appetite through hypothalamic signaling, and enhances glucose-dependent insulin secretion. The key STEP 1 trial demonstrated that semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% over 68 weeks in adults with obesity or overweight with at least one weight-related comorbidity, compared to 2.4% with placebo.

The clinical distinction matters. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for weight management at 2.4 mg weekly. Same molecule, different approved indications, different dose ceilings. When a physician prescribes Ozempic for weight loss in a patient without diabetes, that is off-label use. Off-label prescribing is legal and common across medicine, but it carries specific informed-consent obligations.

The HealthRX Medical Team's Prescriber-Channel Analysis

The HealthRX Medical Team finds Handler's case clinically instructive because it highlights a prescriber-channel question that many patients do not think to ask: who is writing the GLP-1 prescription, and what is their training in metabolic medicine?

Anti-aging and "longevity" clinics became significant prescribers of GLP-1 agonists between 2021 and 2023. These practices often operate outside the traditional referral pathway of primary care to endocrinology or obesity medicine. A 2023 analysis published in JAMA Internal Medicine found that off-label semaglutide prescriptions surged substantially during this period, with a meaningful share originating from non-endocrinology, non-primary care clinicians.

The HealthRX Medical Team recommends that any patient considering GLP-1 therapy confirm the following with their prescriber:

Baseline metabolic screening. Before initiating semaglutide, patients should have fasting glucose, HbA1c, lipid panel, hepatic function, and renal function assessed. A 2022 Endocrine Society position statement reinforces that GLP-1 agonists are not cosmetic interventions and require metabolic context.

Contraindication review. Semaglutide carries a boxed warning for medullary thyroid carcinoma risk based on rodent studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Prescribers should document thyroid history before writing the first prescription, per the Ozempic prescribing information.

Dose titration protocol. The standard Ozempic titration begins at 0.25 mg weekly for four weeks, increases to 0.5 mg, and can escalate to 1 mg or 2 mg depending on glycemic response and tolerability. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events, reported in 15% to 44% of patients across clinical trials. Rapid dose escalation worsens these effects significantly.

Discontinuation planning. Handler's decision to stop taking Ozempic reflects a pattern seen widely. Weight regain after GLP-1 discontinuation is well-documented. The STEP 1 extension trial showed that participants regained two-thirds of their lost weight within one year of stopping semaglutide. Prescribers should discuss maintenance strategies before initiating therapy, not after a patient decides to quit.

At a glance

Status: Chelsea Handler publicly confirmed Ozempic use in January 2023; she has stated she discontinued the medication.
Drug: Semaglutide (Ozempic), prescribed off-label for weight loss by an anti-aging physician.
No other GLP-1 medications have been publicly linked to Handler.
Clinical significance: Her disclosure spotlighted off-label GLP-1 prescribing by non-specialist physicians and the informed-consent gaps that can accompany it.
Weight regain risk: Clinical data show significant weight regain within 12 months of semaglutide discontinuation without structured maintenance.

Handler's statement that she did not initially know she was taking Ozempic raises a clinical red flag the HealthRX Medical Team considers worth examining. Informed consent for any prescription medication requires that the patient understand the drug's name, its intended purpose, expected benefits, potential side effects, and alternatives. This is not a gray area. The American Medical Association's Code of Medical Ethics is explicit on this point.

The scenario Handler describes, receiving an injection from a physician without clearly understanding it was semaglutide, suggests a breakdown in that consent process. Whether this reflects a communication failure, a practice style common in concierge or anti-aging medicine where multiple interventions are bundled, or Handler's own recollection simplifying a more nuanced conversation is impossible to determine from the public record alone.

What is clear: patients seeking GLP-1 therapy through any channel should know exactly what they are being prescribed. Semaglutide is a potent medication with real physiological effects. It is not a supplement. It is not a vitamin injection. It requires monitoring.

The Broader Pattern Handler's Story Fits

Handler was far from the only public figure to discuss GLP-1 medications in 2023. The cultural moment around Ozempic and Wegovy created enormous consumer demand. But her particular disclosure was notable for its specificity. She named the prescriber type (anti-aging doctor), described the consent gap (didn't know it was Ozempic), and voluntarily discussed discontinuation.

This transparency provided a more complete narrative arc than many celebrity GLP-1 disclosures, which tend to either confirm or deny use without clinical detail. For the HealthRX Medical Team, Handler's account remains a useful teaching case for three reasons: it documents a real prescriber-channel issue, it illustrates the informed-consent obligations that accompany off-label use, and it acknowledges the discontinuation question that too many GLP-1 conversations skip entirely.

The American Board of Obesity Medicine has advocated for GLP-1 prescribing to be guided by clinicians with training in obesity as a chronic disease. That does not mean only board-certified obesity medicine specialists can prescribe semaglutide. Primary care physicians prescribe it routinely and appropriately. But the clinical infrastructure around the prescription, metabolic workup, contraindication screening, titration management, and long-term follow-up, matters as much as the prescription itself.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
FDA Drug Safety Communication: Medications containing semaglutide. https://www.fda.gov/drugs/drug-safety-and-availability/medications-containing-semaglutide-marketed-type-2-diabetes-or-obesity
Ozempic prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
Kaplan LM, et al. Off-label prescribing of semaglutide. JAMA Intern Med. 2023. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2807617
AMA Code of Medical Ethics: Informed Consent. https://www.ama-assn.org/delivering-care/ethics/informed-consent